<div id="readability-page-1"><p>Campbell &amp; CO Investment Adviser LLC purchased a new stake in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 5,480 shares of the company's stock, valued at approximately $1,269,000.</p><ul><li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li></ul><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of  AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter.  Geode Capital Management LLC lifted its stake in  AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company's stock valued at $7,240,169,000 after buying an additional 924,761 shares in the last quarter.  Charles Schwab Investment Management Inc. grew its holdings in  AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock valued at $4,970,848,000 after buying an additional 1,517,222 shares during the last quarter.  Norges Bank acquired a new stake in  AbbVie during the 2nd quarter valued at $4,288,200,000.  Finally, Raymond James Financial Inc. increased its position in  AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds. </p><h2>More AbbVie News</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. <i></i><span>Zacks: AbbVie stock dips — key facts</span></li>    <li><span>Positive Sentiment: </span>AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. <i></i><span>TipRanks: ABBV starts ABBV‑711 trial</span></li>    <li><span>Positive Sentiment: </span>AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. <i></i><span>TipRanks: obesity pipeline update</span></li>    <li><span>Positive Sentiment: </span>Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. <i></i><span>FiercePharma: Skyrizi top TV ad spender</span></li>    <li><span>Neutral Sentiment: </span>AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. <i></i><span>PR Newswire: AbbVie topline EPCORE DLBCL‑1</span></li>    <li><span>Negative Sentiment: </span>Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. <i></i><span>Seeking Alpha: Genmab down after Epkinly trial data</span></li> </ul><h2>Wall Street Analysts Forecast Growth</h2><ul><li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li></ul><p>A number of brokerages have recently commented on ABBV. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $280.00 price objective for the company. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Piper Sandler  reissued an &#34;overweight&#34; rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. DZ Bank lowered shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $237.00 price target for the company. in a research note on Tuesday, November 4th. Finally, Morgan Stanley upped their price objective on AbbVie from $261.00 to $269.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned  a Hold rating to the company's stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $247.84.</p><p><b>Get Our Latest Report on ABBV</b></p><h2>AbbVie Price Performance</h2><ul><li>This ETF Is Proof That the Healthcare Rebound Is Real</li></ul><p>AbbVie stock opened at $214.38 on Monday. The stock has a market capitalization of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a 50 day simple moving average of $226.80 and a 200-day simple moving average of $216.65. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analysts' expectations of $15.58 billion. During the same period last year, the firm earned $3.00 EPS. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  On average, analysts forecast that  AbbVie Inc. will post 12.31 earnings per share for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a positive change from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is presently 496.97%. </p><h2>AbbVie Company Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AbbVie</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Campbell & CO Investment Adviser LLC acquired 5,480 shares of AbbVie Inc. (NYSE:ABBV) in Q3, valued at approximately $1.27 million. Other institutional investors, including Vanguard and Geode Capital, also increased their stakes in AbbVie. Analysts have mixed sentiments about AbbVie, with some raising price targets and ratings, while others express concerns over recent clinical trial results. The stock has a consensus rating of "Moderate Buy" and a price target of $247.84, with a current market cap of $378.89 billion.</p>

Campbell & CO Investment Adviser LLC Buys Shares of 5,480 AbbVie Inc. $ABBV